Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: Metabolic systems approaches update molecular insights of clinical phenotypes and cardiovascular risk in patients with homozygous familial hypercholesterolemia

Fig. 4

ASCVD-associated metabolite and protein alterations in the sera of HoFH patients. a Dot histogram of metabolite levels in HoFH patients with and without ASCVD events (concentration, nmol/mL). Mann–Whitney U test were used for each comparison. b Functionally grouped network of enriched pathways of differentiated proteins in patients with ASCVD events. c Enriched GO categories of differentiated proteins. BP biological process, CC cellular component, MP molecular function. d Topology analysis of pathway enrichment and impact from the joint pathway of differentially expressed proteins and metabolites. e Metabolite-protein interaction network. f Topology analysis of pathway enrichment and impact from the joint-pathway of differentially expressed proteins and metabolites. LPA 16:0 lysophosphatidic acid 16:0, LPC-O 18:0 lysophosphocholine alkyl − 18:0, LPC 20:4 lysophosphocholine 20:4, 12,13-EpOME 12,13-epoxyoctadecenoic acid, Cer (d18:1_16:0) Ceramide (d18:1_16:0). Other abbreviations are seen in Figs. 1 and 2

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us